Senzime
Revolutionizing perioperative care. Smart and simple.
Revolutionizing perioperative care. Smart and simple.
Senzime is a leading global medical device company, developing precision-based patient monitoring solutions that drive a global paradigm shift in perioperative patient safety. Our cutting-edge solutions TetraGraph and ExSpiron 2Xi are powered by proprietary, smart algorithms to monitor neuromuscular and respiratory functions during and after surgery. With our dedicated team and strong partnerships, we are on a global mission to safeguard every patient's journey, from anesthesia to recovery. Established in 1999, Senzime is backed by long-term investors and listed on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the New York OTCQX market (SNZZF). #senzime #tetragraph #patientsafety #tofmonitoring #anesthesia
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Funding Round | $309.34K | - | 11 Apr 2017 | |
| Grant | €50.00K | 1 | EASME - EU Executive Agency for SMEs | 01 Jun 2015 |
No recent news or press coverage available for Senzime.
We care about your data, and we'd love to use cookies make your experience better.
